Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist.

Department of Respiratory Care, Children's Memorial Hospital, 2300 Children's Plaza, Box 58, Chicago, IL 60614, USA.
Respiratory care (Impact Factor: 1.84). 06/2009; 54(5):641-57. DOI: 10.4187/aarc0446
Source: PubMed

ABSTRACT Cystic fibrosis (CF) is a complex genetic disease characterized by lung infections that lead to early morbidity and death. Pathogens that commonly infect the lungs of patients with CF include Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa, and Burkholderia cepacia. Aggressively treating pulmonary infection with antibiotics has contributed to improved survival in patients with CF but has also promoted multiple-drug-resistant bacteria. Other complexities include the ability of bacteria to form biofilms, which makes them more resistant to antibiotics, and emerging pathogens in CF, of which the clinical importance is not yet clear. Increasing evidence of patient-to-patient transmission of CF pathogens led the Cystic Fibrosis Foundation to produce evidence-based infection-control recommendations, which stress 4 principles: standard precautions, transmission-based precautions, hand hygiene, and care of respiratory equipment. Respiratory therapists need to know and follow these infection-control recommendations. Cohorting patients infected with B. cepacia complex is one of several interventions successful at keeping the spread of this pathogen low, but cohorting patients who are infected/colonized with other microbes is controversial, the main argument of which is not being certain of a patient's present respiratory culture status at any given patient visit.

  • Source
    • "It is characterized by abnormal transport of chloride and sodium across epithelium, leading to thick, viscous secretions [1]. The hallmark pulmonary symptoms of CF are accumulation of thick, sticky mucus , frequent chest infections and coughing or shortness of breath [2]. Such pulmonary infections are the primary cause of morbidity and mortality among patients with CF; endobronchial infection with Pseudomonas aeruginosa is difficult to treat since aminoglycosides active against P. aeruginosa penetrate sputum poorly. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cystic fibrosis (CF) patients are suffering from multiple often chronic endobronchial infection. The stiff mucus in these patients represents a compartment, which cannot easily be reached by systemic treatment. While bacterial infections are now successfully treated with repeated inhalation of antibiotics such as tobramycine, 57% of CF patients are colonized by Aspergillus species. About 10-20% of colonized patients develop symptoms of allergic bronchopulmonary aspergillosis (ABPA). While current standard of treatment of ABPA in CF patients is to suppress the allergy related symptoms by administration of glucocorticoids, itraconazole (ITRA), administered orally at high doses, can alleviate the symptoms of ABPA. However, no inhalable formulation of ITRA is available to enable local treatment of aspergillosis. The aim of this study was to describe an aqueous nanosuspension of ITRA and to characterize the pharmacokinetics after single dose inhalation. Using wet-milling with organic milling beads, a stable nanosuspension with particle size in the range of 200nm and an ITRA concentration of 20% (v/w) could be obtained, using polysorbate 80 at a concentration of 14% relative to ITRA. The suspension was stable if stored at 8°C for 3months without particle growth and could be nebulized using standard nebulizer technologies including mesh technology and pressured air nebulizers. A 10% suspension was well tolerated upon repeated dose inhalation once daily for 7days at a predicted dose of 45mg/kg in rats. A single dose inhalation at a predicted dose of 22.5mg/kg resulted in maximum lung tissue concentration of 21.4μg/g tissue with a terminal half-life of 25.4h. Serum concentrations were lower, with a maximum concentration of 104ng/ml at 4h after dosing and a terminal half-life of 10.5h. The data indicate that ITRA nanosuspension represents an interesting formulation for inhaled administration in CF patients suffering from ABPA. High and long lasting lung tissue concentrations well above the minimal inhibitory concentration of Aspergillus species enable once daily administration with minimal systemic exposure.
    European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 10/2012; 83(1):44-53. DOI:10.1016/j.ejpb.2012.09.018 · 4.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper examines the role of image-based navigation in the context of characterizing the standard long baseline navigation used by underwater vehicles for survey applications. Our work is based on looking at the displacement estimate that can be derived from registering overlapping imagery of the seafloor. Our approach is realistic in that it does not require large overlap and in that it can handle translational and rotational motions between image pairs in an unstructured terrain. We demonstrate our approach on a photographic survey conducted by the Argo towed vehicle covering several square kilometers off of Guam in the Pacific Ocean over a period of almost two months
    Intelligent Robots and Systems, 2001. Proceedings. 2001 IEEE/RSJ International Conference on; 02/2001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bacteria infect the respiratory tract early in the course of cystic fibrosis disease, often fail to be eradicated, and together with an aggressive host inflammatory response, are thought to be key players in the irreversible airway damage from which most patients ultimately die. Although incompletely understood, certain aspects of the cystic fibrosis airway itself appear to favor the development of chronic modes of survival, in particular biofilm formation; this and the development of antibiotic resistance following exposure to multiple antibiotic courses lead to chronic, persistent infection. In addition to the common cystic fibrosis pathogens, such as Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa, several newer species are becoming more common. Furthermore, new molecular techniques have led to the identification of multiple different organisms within respiratory secretions, many of which are not cultured with conventional tools. Future work should aim to develop clinically applicable methods to identify these and to determine which have the potential to impact pulmonary health. We outline the basic tenets of infection control and treatment.
    Respiratory care 06/2009; 54(5):628-40. DOI:10.4187/aarc0492 · 1.84 Impact Factor
Show more


1 Download
Available from